Treatment algorithms for type 2 diabetes recommend weight loss for disease management. The safety and efficacy of treatment with phentermine (PHEN)/topiramate (TPM) extended release (ER) plus lifestyle modification for weight loss and glycemic benefits were assessed in two randomized, double-blind, placebo-controlled 56-week studies of obese/overweight adults with type 2 diabetes.
resistance, dysregulated secretion of adipocytokines, and systemic inflammation (2, 3) . Additionally, weight loss has long been known to enhance insulin sensitivity and improve glycemia in type 2 diabetes patients (4, 5) . This has been underscored more recently by the Look AHEAD Study, which demonstrated that structured lifestyle modifications led to progressive decrements in HbA 1c level as a function of the amount of weight loss achieved over the range of 5% to $15%, together with improvements in dyslipidemia and blood pressure (6, 7) . Despite these results, treatment algorithms for type 2 diabetes, while advocating changes in diet and physical activity, have not until recently emphasized the treatment of obesity as a primary strategy for the management of type 2 diabetes (1, (8) (9) (10) (11) (12) . The underemphasis on weight-loss therapy may relate to difficulties in maintaining clinically meaningful reductions in body weight through diet and lifestyle changes alone (4, 9, 13) , and to the paucity of effective and safe obesity medications (14). Indeed, approved pharmacologic weight-loss agents have historically demonstrated only modest efficacy (13, 15, 16) , emphasizing the clear need for therapeutic options that produce more robust and sustained weight loss in patients with type 2 diabetes.
The recent approval of new medications with an indication for long-term weight management, together with lifestyle modification, have enabled the development of more effective strategies and medical models for the treatment of obesity as a disease (17) . For example, the complications-centric approach of the American Association of Clinical Endocrinologists (AACE) emphasizes that the presence and severity of complicationsdrather than BMIdshould be the primary factors used in clinical decision making regarding weight-loss treatment modality and intensity (2) . In this context, given that type 2 diabetes is a major complication of obesity, it is imperative that the new, enhanced treatment options for obesity be examined as a primary therapeutic modality (18) .
The combination of phentermine (PHEN)/topiramate (TPM) extended release (ER) is a weight-loss medication approved by the U.S. Food and Drug Administration in 2012 as an adjunct to lifestyle modification for long-term treatment of obesity and overweight (19) . PHEN/TPM ER has been shown to improve cardiometabolic parameters (20, 21) and prevent progression to type 2 diabetes in patients with prediabetes and/ or metabolic syndrome (22) . This article presents two randomized, placebocontrolled clinical studies (the OB-202/ DM-230 Study and a post hoc analysis of the CONQUER Study, a 56-week phase 3 trial in obese adults with obesity-related comorbid conditions) in patients with a type 2 diabetes over a broad range of severity, treated with lifestyle modification and PHEN/TPM ER. The subset of patients with type 2 diabetes in the CONQUER Study were treated with metformin or diet alone at study entry (21) , while patients in the OB-202/DM-230 had more longstanding diabetes that required more intensive therapy.
RESEARCH DESIGN AND METHODS

OB-202/DM-230 Study
Study Design
The DM-230 Study was a 28-week, double-blind continuation of a 28-week, phase 2, randomized, double-blind, placebo-controlled study (OB-202) assessing the efficacy and safety of PHEN and TPM in the glycemic management of obese subjects with type 2 diabetes. Subjects were actively managed to standard of care for their comorbidities including the options to add, discontinue, or adjust the dose of medications for type 2 diabetes, hypertension, and/or dyslipidemia. All subjects received lifestyle counseling at randomization in the OB-202 Study and again at their first DM-230 Study visit, including recommendations for caloric reduction (by 500 kcal/day), daily exercise as tolerated, and increased water intake. This study was conducted between 12 June 2007 and 17 October 2008, and was approved by institutional review boards at each site. All subjects provided written informed consent.
Randomization and Masking
In the OB-202 Study, subjects were randomized 1:1 to receive placebo or active treatment, consisting of once-daily PHEN 15 mg, taken in the morning, and oncedaily TPM 100 mg, taken in the afternoon. There was a 4-week titration to the randomized dose, followed by an additional 24 weeks of treatment. 
Study Outcomes
The primary end point was the change in HbA 1c levels between entry into the OB-202 Study and the end of treatment (week 56) in the DM-230 Study. Additional efficacy end points included percentage of weight loss; percentage of subjects achieving HbA 1c levels of #7% and #6.5% (#53 and #48 mmol/mol); changes in concomitant use of antidiabetic medications; and changes in fasting glucose and fasting insulin levels, insulin sensitivity (by HOMA of insulin resistance and whole-body insulin sensitivity index), blood pressure, and lipid parameters. Safety end points included treatment-emergent adverse events (TEAEs) and hypoglycemic events.
CONQUER
The CONQUER Study was a 56-week, double-blind, placebo-controlled study in which obese and overweight adults (BMI 27-45 kg/m 2 ; no lower limit for subjects with type 2 diabetes) with two or more weight-related comorbidities were randomized to receive placebo, PHEN/TPM ER 7.5 mg/46 mg (7.5/46), or PHEN/TPM ER 15/92 (21) . The full study design and the efforts made to lower HbA 1c level in a subset of patients with type 2 diabetes were previously published (21) . This report addresses previously unpublished data from the predefined subset of CONQUER subjects with type 2 diabetes at entry. Subjects were excluded if their fasting glucose level was .13.32 mmol/L or if they were taking antidiabetic drugs other than metformin at baseline. Presented in this analysis are new data pertaining to the type 2 diabetes subset, including the percentage of subjects achieving HbA 1c levels of #7% and #6.5% (#53 and #48 mmol/mol), changes in the concomitant use of antidiabetic medications, effects on BP and lipid parameters, and safety data such as TEAEs and hypoglycemic events.
Statistical Analysis for the OB-202/DM-230 Study and the CONQUER Substudy
In both studies, all efficacy analyses were conducted on the intent-to-treat (ITT) population, which includes all subjects who took one or more doses of the study drug or placebo and had undergone one or more post-treatment measurements. End points were analyzed at each assessment time through week 56, with the last observation carried forward (LOCF) to impute any missing values. Percentage of weight loss, HbA 1c level, and fasting glucose level were also assessed over time by an observed case analysis, including subjects receiving treatment who provided a measurement at each assessment time point (modified ITT [mITT]). The timing of visits and assessments was identical between studies.
ANCOVA was used to evaluate continuous efficacy variables using baseline values as a covariate and treatment as a fixed effect. Descriptive statistics as well as estimates of least squares (LS) mean, SE, and 95% CIs were computed for all continuous efficacy end points. Analyses of proportions of categorical end points were performed on the ITT population with LOCF by logistic regression. Changes in number and dosages of antidiabetic medications were evaluated using a net scoring system, and treatment group differences were analyzed by the x 2 test. All statistical testing was two-sided and performed at the 0.05 significance level. (Table 1) , with the exception of a higher percentage of females in the PHEN/TPM ER group. The majority of subjects (60.0%) had received a diagnosis of type 2 diabetes $5 years previously at screening, and the mean disease duration was 9 years, with only two placebo subjects (4%) and five PHEN/TPM ER subjects (7%) having received a diagnosis of type 2 diabetes ,1 year previously. Eighty-nine percent of subjects were taking one or more oral antidiabetic medications, and 60% were taking two or more medications. In total, 60.8% of subjects were taking metformin, 32.3% were taking sulfonylureas (SFUs), 3.1% were taking thiazolidinediones, and 3.1% were taking dipeptidyl peptidase-4 inhibitors; 33.8% were taking another class of medication, including SFUs but excluding insulin. The study excluded subjects receiving injectable antidiabetic medications, including insulin and GLP-1 receptor agonists. The baseline HbA 1c level was 8.7% (72 mmol/mol).
CONQUER
Of the 2,487 subjects randomized in the CONQUER Study, 388 (15.6%) had type 2 diabetes at baseline and thus were eligible to be included in this analysis (157 of whom were randomized to receive placebo, 67 to the PHEN/TPM ER 7.5/ 46 group, and 164 to the PHEN/TPM ER 15/92 group); 74.5% of subjects completed all study visits ( Supplementary  Fig. 1B ). Baseline demographic and clinical characteristics of the subjects with type 2 diabetes were similar across treatment groups (Table 1 ). The patients in CONQUER had shorter duration and less severe diabetes compared with those in the OB-202/DM-230. At baseline, the mean number of medications per subject was 0.6 (58.0% were taking metformin; ,1% were taking an SFU, a thiazolidinedione, or a dipeptidyl peptidase-4). The majority of subjects (60.3%) had received a diagnosis of type 2 diabetes within #5 years. The baseline HbA 1c level was 6.8% (51 mmol/mol).
Weight Loss and Glycemic Control at Week 56
OB-202/DM-230
Subjects randomized to receive PHEN/ TPM ER had LS mean percent weight loss of 9.6% vs. 2.6% with placebo by mITT analysis (P , 0.0001; Fig. 1A ). An ITT-LOCF analysis also demonstrated significantly greater weight loss with PHEN/TPM ER therapy (Fig. 1A) . At week 56, 65% of PHEN/TPM ER subjects had achieved $5% weight loss vs. 24% of the placebo group (ITT-LOCF; P , 0.0001), and 37% of PHEN/ TPM ER subjects had $10% weight loss vs. 9% of placebo subjects (ITT-LOCF; P = 0.0004).
Regarding the effects on glycemic control in the OB-202/DM-230, subjects assigned to receive PHEN/TPM ER had a greater LS mean decrease in HbA 1c level of 21.6% (217.5 mmol/mol) vs. 21.2% (213.1 mmol/mol) in the placebo group (mITT and ITT-LOCF; P , 0.05; Fig. 1B) . In addition, a significantly greater percentage of PHEN/TPM ER subjects achieved the HbA 1c goal of #7.0% (#53 mmol/mol) compared with placebo subjects (53% vs. 40%), as well as the HbA 1c target of #6.5% (#48 mmol/mol) compared with placebo (32% vs. 16%; ITT-LOCF; P , 0.05, all comparisons; Fig. 2A ). Significantly greater improvements in fasting glucose levels were also observed in the PHEN/TPM ER group versus the placebo group (22.3 and 21.5 mmol/L, respectively, from baseline levels of 9.8 and 9.5 mmol/L; P , 0.05; Supplementary Fig. 2A ). Other glycemic parameters are presented in Supplementary  Table 2 .
In these actively managed subjects, a greater percentage of PHEN/TPM ERtreated subjects decreased the number of antidiabetic medications taken during the study period compared with the placebo group (18.7% vs. 5.5%, respectively); conversely, fewer PHEN/TPM ER-treated subjects required an increase in antidiabetic medications (21.3% vs. 29.1%, respectively; Fig. 2C ).
CONQUER PHEN/TPM ER-treated patients with type 2 diabetes exhibited greater reductions in both body weight and HbA 1c values than observed in the placebo group, as previously reported (21) . We now report that a greater number of PHEN/TPM ER-treated subjects achieved HbA 1c targets than placebo subjects (Fig. 2B) . These improvements in glycemia were achieved despite greater reductions in antidiabetic medications, as well as less need to augment diabetes therapy, in the PHEN/TPM ER groups compared with the placebo group (Fig. 2D) .
Effects on Cardiometabolic Parameters
Treatment with PHEN/TPM ER and lifestyle modifications led to reductions in SBP, DBP, and triglyceride levels, and increments in HDL cholesterol, as shown in Supplementary Table 2. In particular, in the OB-202/DM-230 Study, treatment with PHEN/TPM ER resulted in a 27.2 mm Hg LS mean reduction in SBP at week 56, which was significantly greater than the 22.4 mm Hg decrease observed after treatment with placebo (P , 0.05; ITT-LOCF; Supplementary Table 2) . DBP was decreased in both treatment groups (22.6 vs. 21.7 mm Hg), although the difference was not significant.
Safety
OB-202/DM-230
The most commonly reported TEAEs in the PHEN/TPM ER group that occurred more often than in the placebo group over 56 weeks were paraesthesia, constipation, and nausea (Supplementary Table 3 ). The majority of adverse events (AEs) were mild (placebo group 69.1%, PHEN/TPM ER group 60.0%). There were markedly fewer TEAEs reported during the DM-230 extension (weeks 28 through 56) than during the OB-202 Study (weeks 0-28), particularly in the PHEN/TPM ER group. Discontinuation of study drug due to AEs was rare and occurred only in one subject from the PHEN/TPM ER group (treatment-related disturbance in attention and asthenia, which was considered moderate in severity and resolved without complication). A similar number of serious AEs (SAEs) were reported in the two study groups, none of which was classified as treatment related (Supplementary Table 3) .
During the 56 weeks of treatment, 58 hypoglycemic events were reported in 17 OB-202/DM-230 subjects (5 treated with placebo; 12 treated with PHEN/TPM ER; safety population; Supplementary 29 (53) 49 (65) 66 (42) 27 (40) 61 (37) Antidiabetic medication use Mean number of medications per subject (SD) 1.6 (0.9) 1.6 (0.9) 0.6 (0.5) 0.6 (0.5) 0.6 (0.5) 1 oral medication, n (%)
16 (29) 21 (28) 91 (58) 40 (60) 95 (58) 2 oral medications, n (%)
26 (47) 37 (49) 1 (1) 1 (1) 2 (1) $3 oral medications, n (%) 7 (13) 9 (12) *Other includes American Indian, Alaskan Native, Native Hawaiian, or other Pacific Islander. †Dyslipidemia was defined as triglycerides $200 and #400 mg/dL or requirement for two or more medications to achieve control, defined as ,200 mg/dL. ‡Metabolic risk factors included elevated fasting glucose levels, elevated waist circumference, elevated triglyceride levels, reduced HDL cholesterol level, and elevated blood pressure, per the criteria for metabolic syndrome outlined by Alberti et al. (28) . Table 3 ). These events appeared to be related to concomitant antidiabetic medication use; in 90% of events (n = 52), subjects were also being treated with an SFU. All events were mild to moderate in severity; none was considered severe. Ten hypoglycemic events (15.6%) in three study subjects (one in the placebo group; two in the PHEN/TPM ER group) were deemed treatment related.
CONQUER
In assessing safety in the subset of CONQUER patients with type 2 diabetes, the majority of AEs were mild to moderate in severity and were similar to the overall safety set population (Supplementary Two SAEs (chest pain and nephrolithiasis) (PHEN/TPM ER 15/92 group) were classified as treatment related. Study drug was withdrawn, and both events resolved. No single type of SAE was reported in more than one PHEN/TPM ER-treated subject or in more than two subjects overall (21) . During 56 weeks of treatment, there were six reports of hypoglycemia in five subjects, as follows: four events in the placebo group (three mild, one severe), one in the PHEN/TPM ER 7.5/46 group (mild), and one in the PHEN/TPM ER 15/ 92 group (mild). None was classified as treatment related or led to study drug discontinuation; all events resolved.
CONCLUSIONS
The analysis of two clinical trials, OB-202/ DM-230 and CONQUER, allowed for the assessment of efficacy and safety of PHEN/TPM ER treatment in patients with type 2 diabetes over a wide range of disease severity and chronicity. The OB-202/DM-230 Study enrolled patients with chronic, moderate-to-severe type 2 diabetes, with the majority of patients taking multiple glucose-lowering medications, while CONQUER patients had shorter-term type 2 diabetes with a lower baseline mean HbA 1c level treated with diet and/or metformin. In both studies, treatment with lifestyle modification plus PHEN/TPM ER resulted in weight loss (on average 7-10%), which was sustained for 1 year. While individuals with type 2 diabetes tend to have more difficultly achieving and maintaining weight loss than those without type 2 diabetes (23, 24) , these data indicate that weightloss treatment with PHEN/TPM ER plus lifestyle modification can be highly effective. Importantly, PHEN/TPM ER-assisted weight loss was accompanied by improvements in glycemic control, together with less need for conventional glucose-lowering medications. In the OB-202/DM-230 Study, treatment with PHEN/TPM ER The degree of weight loss in the PHEN/ TPM ER-treated groups, sustained over 1 year, met or exceeded the 5-7% weightloss goal recommended by the American Diabetes Association for patients with type 2 diabetes (1) . Approximately 60% of all PHEN/TPM ER-treated patients with type 2 diabetes in OB-202/DM-230 and CONQUER achieved $5% weight loss. These results align with AACE 2013 algorithms advocating weight loss, including medication-assisted weight loss, as a primary treatment approach in type 2 diabetes (2). These algorithms emphasize the utility of using lifestyle modification with or without the addition of weightloss medications for the treatment of obesity-related complications, including type 2 diabetes, in patients with a BMI $27 kg/m 2 . Our results are compatible with those of previous studies demonstrating the beneficial effects of weight loss in patients with type 2 diabetes, whether achieved by lifestyle modification alone (4-7) or assisted by weight-loss medications (25, 26 (26) .
In general, PHEN/TPM ER was well tolerated, with similar safety observed between patients with type 2 diabetes and those without type 2 diabetes in the overall CONQUER Study population (21) . Hypoglycemic events were relatively uncommon, and were observed in both studies in the placebo-and drug-treated groups. The most significant finding was the higher prevalence of hypoglycemia in the OB-202/DM-230 Study, which was often associated with the use of insulin secretagogues without dose adjustments despite improvements in glycemic parameters as patients lost weight. Although almost all hypoglycemic events were mild to moderate in severity, it is important to emphasize that weight loss increases the risk of hypoglycemia in patients with type 2 diabetes, and efforts should be undertaken to minimize these risks (2). Accordingly, blood glucose levels should be measured prior to and during treatment with PHEN/TPM ER in patients with type 2 diabetes, and reductions in doses of non-glucose-dependent antidiabetic medications should be considered at the start of negative energy balance in order to reduce the risk of hypoglycemia (19, 27) .
The current studies have certain limitations. The DM-230 Study was an extension of the OB-202 Study; although all patients who completed the OB-202 were eligible to enroll in the DM-230, more placebo patients (n = 21) elected not to enroll compared with the PHEN/ TPM ER-treated patients (n = 14), and thus the original 1:1 randomization ratio was not maintained in the DM-230. In both the DM-230 and CONQUER, all patients received lifestyle modification treatment, and thus the benefits presented here reflect a combination of PHEN/TPM ER plus lifestyle modification (21) . Also, since both studies involved active management to standards of care, changes in the use of concomitant medications for the treatment of hypertension, dyslipidemia, and hyperglycemia are likely to have affected related study variables, often masking the true clinical difference between patients randomized to receive PHEN/ TPM ER versus placebo. However, active management was applied consistently by treatment-blinded clinicians across placebo and PHEN/TPM ER treatment groups in an effort to approximate real-world clinical practice. Even so, additional longer-term data will add to the understanding of the benefits and risks of prolonged PHEN/TPM ER use in patients with type 2 diabetes.
In conclusion, treatment with PHEN/ TPM ER plus lifestyle modification produced significant weight loss and improvements in glycemic control, together with reductions in blood pressure and triglyceride levels, over 56 weeks in obese/overweight patients with type 2 diabetes. The medication was generally well tolerated. These data indicate that medicationassisted weight loss, using PHEN/TPM ER, may constitute a new and effective approach for treating obese and overweight patients with type 2 diabetes. Indeed, consistent with the AACE algorithm (2), weight-loss therapy can be considered integral to the treatment of type 2 diabetes together with conventional glucose-lowering medications, and, in fact, can be used as a primary therapeutic modality to improve glycemic control in type 2 diabetes.
